$185.58
1.33% yesterday
NYSE, May 08, 10:10 pm CET
ISIN
US00287Y1091
Symbol
ABBV
Sector
Industry

AbbVie Stock price

$185.58
+9.91 5.64% 1M
-13.92 6.98% 6M
+7.88 4.43% YTD
+25.13 15.66% 1Y
+34.62 22.93% 3Y
+101.62 121.03% 5Y
+120.34 184.46% 10Y
NYSE, Closing price Thu, May 08 2025
-2.51 1.33%
ISIN
US00287Y1091
Symbol
ABBV
Sector
Industry

Key metrics

Market capitalization $328.29b
P/E (TTM) P/E ratio 78.94
P/S ratio (TTM) P/S ratio 5.72
P/B ratio (TTM) P/B ratio 98.53
Dividend yield 3.39%
Last dividend (FY24) $6.29
Revenue growth (TTM) Revenue growth 5.45%
Revenue (TTM) Revenue $57.37b
EBIT (operating result TTM) EBIT $17.62b
Cash position $5.56b
EPS (TTM) EPS $2.35
P/E forward 28.34
P/S forward 5.48
Short interest 0.95%
Show more

Is AbbVie a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,791 stocks worldwide.

AbbVie Stock Analysis

Unlock Scores for Free

Analyst Opinions

30 Analysts have issued a AbbVie forecast:

19x Buy
63%
10x Hold
33%
1x Sell
3%

Analyst Opinions

30 Analysts have issued a AbbVie forecast:

Buy
63%
Hold
33%
Sell
3%

Financial data from AbbVie

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
57,367 57,367
5% 5%
100%
- Direct Costs 14,893 14,893
12% 12%
26%
48,744 48,744
30% 30%
85%
- Selling and Administrative Expenses 16,414 16,414
287% 287%
29%
- Research and Development Expense 8,443 8,443
15% 15%
15%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT 17,617 17,617
2% 2%
31%
Net Profit 4,171 4,171
30% 30%
7%

In millions USD.

Don't miss a Thing! We will send you all news about AbbVie directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

AbbVie Stock News

Neutral
GlobeNewsWire
one day ago
NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV).
Neutral
PRNewsWire
3 days ago
NORTH CHICAGO, Ill. , May 6, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Bank of America Securities Healthcare Conference on Wednesday, May 14, 2025.
Positive
CNBC
3 days ago
President Donald Trump signed an executive order to incentivize drug manufacturing in the U.S. The order comes ahead of Trump's planned tariffs on pharmaceuticals imported into the U.S.
More AbbVie News

Company Profile

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease; metabolic diseases, comprising thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Head office United States
CEO Robert Michael
Employees 55,000
Founded 2011
Website www.abbvie.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today